Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | June 11, 2024 | June 12, 2024 |
| Caris Life Sciences, Inc.CAI · Entity 3706 | Director | August 14, 2026 | August 14, 2026 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director | June 26, 2019 | June 28, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date June 11, 2024 · Filed June 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,159 |
Reported balance
After 2024-06-11 transaction · row 1
1 source rowRow 1 · 2024-06-11 · Purchase · Acquired 10,000 · Balance 151,159 |
Caris Life Sciences, Inc.
Report date August 14, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,863 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 13,192 · Balance 62,863 F1: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Odonate Therapeutics, Inc.
Report date June 26, 2019 · Filed June 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,231 |
Reported balance
After 2019-06-26 transaction · row 1
1 source rowRow 1 · 2019-06-26 · Purchase · Acquired 19,231 · Balance 23,231 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SPECTRUM PHARMACEUTICALS INC
Report date July 31, 2023 · Filed August 01, 2023
Section 16 reporting ended · disclosed 2023-08-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 1
1 source rowRow 1 · 2023-07-31 · Disposition to issuer · Disposed 295,244 · Balance 0 F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 | Direct | 0 |
Reported balance
After 2023-07-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger.
F2: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,
F3: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 14, 2026 21:40 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 13,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001724161-26-000008 · wk-form4_1786743631.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,863 F1 · shares: Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. Read SEC document |
| May 11, 2026 Filed May 12, 2026 12:22 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | PurchaseCommon Stock | 31,050 | $16.15 | $501,426.45 |
DisclosureSEC source: 0001724161-26-000005 · wk-form4_1778588549.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,671 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.13 to $16.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 23:09 UTC | Caris Life Sciences, Inc. CAI · Entity 3706 | GrantCommon Stock | 2,492 | $20.06 | $49,989.52 |
DisclosureSEC source: 0001724161-26-000002 · wk-form4_1772233759.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,621 F1 · kind: Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 22:00 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | PurchaseCommon Stock | 10,000 | $1.11 | $11,100.00 |
DisclosureSEC source: 0001104659-24-070931 · tm2417085-1_4seq1.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,159 Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:01 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 81,225 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001104659-24-065700 · tm2415689-4_4seq1.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,225 Underlying: Common Stock · 81,225 shares Expires 2034-05-23 F3 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F2 · derivative.exercise_date: Stock options that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2024 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:01 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 53,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-065700 · tm2415689-4_4seq1.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,159 F1 · shares: Restricted stock units that (1) vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders which is at least 50 weeks after the immediately preceding year's annual meeting, and (2) were granted on the date of the Issuer's 2024 Annual Meeting of Stockholders in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:05 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerStock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $1.13 | Not disclosed |
DisclosureSEC source: 0000899243-23-017668 · doc4.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · price: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3 · price: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F2 · derivative.exercise_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3 · derivative.exercise_date: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. F2 · derivative.expiration_date: Stock options of the Issuer (the "Company Options") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration, F3 · derivative.expiration_date: (Continued from Footnote 2) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 17:05 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | Disposition to issuerCommon Stock, $0.001 par value | 295,244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-017668 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation ("Acquiror"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the "Upfront Consideration") and (b) a contingent value right ("CVR") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the "Merger Consideration") on the effective date of the merger. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:45 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantStock Option (right to buy) · Derivative | 5,005 | $0.00 Strike: $5.69 | $0.00 |
DisclosureSEC source: 0001104659-23-086925 · tm2322708-2_4seq1.xml · derivative · entry 3 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,005 Underlying: Common Stock · 5,005 shares Expires 2033-07-31 F5 · price: These derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for these derivative securities. F4 · derivative.exercise_date: Stock options were granted in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy on the date the Issuer appointed the Reporting Person to serve on its Board of Directors in accordance with the Merger Agreement. One-third of these stock options are scheduled to vest on each of July 31, 2024, 2025 and 2026, assuming continued service through the applicable vesting date. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:45 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 34,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-086925 · tm2322708-2_4seq1.xml · nonDerivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,409 F3 · shares: Restricted stock units were granted in accordance with the Issuer's Nonemployee Director Compensation & Grant Policy on the date the Issuer appointed the Reporting Person to serve on its Board of Directors in accordance with the Merger Agreement. One-third of these restricted stock units are scheduled to vest on each of July 31, 2024, 2025 and 2026, assuming continued service through the applicable vesting date. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:45 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 52,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-086925 · tm2322708-2_4seq1.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,642 F1 · price: On July 31, 2023, pursuant to the terms of an Agreement and Plan of Merger, dated as of April 24, 2023 (the "Merger Agreement"), by and among the Issuer, Spectrum Pharmaceuticals, Inc. ("Spectrum") and Spade Merger Sub 1, Inc. ("Merger Sub"), Merger Sub merged with and into Spectrum, with Spectrum continuing as the surviving corporation and as a wholly owned subsidiary of the Issuer (the "Merger"). At the effective time of the Merger, each share of Spectrum common stock issued and outstanding immediately prior to the effective time automatically converted into (i) 0.1783 of a newly issued share of the Issuer's Common Stock, without interest, plus the right, if any, to receive cash in lieu of fractional shares, and (ii) one non-tradeable contingent value right ("CVR"). F2 · price: The CVRs represent contractual, contingent rights to receive milestone payments in the form of future conditional payments worth up to an aggregate maximum amount of $0.20, which amount is settleable in cash, additional shares of the Issuer's Common Stock or a combination of cash and additional shares of Common Stock, at the Issuer's sole discretion, upon the achievement of certain sales milestones related to Spectrum's product ROLVEDON. The minimum payment on each CVR is zero and the maximum payment is $0.20. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 20:17 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | PurchaseCommon Stock, $0.001 par value | 50,000 | $0.45 | $22,500.00 |
DisclosureSEC source: 0000899243-22-037526 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,244 F1 · price: This transaction was executed in multiple trades at prices that when rounded to the nearest cent were equal to $0.45. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Excludes 25,000 restricted stock units granted on August 31, 2022. Read SEC document |
| October 27, 2022 Filed Oct 27, 2022 18:35 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 50,000 | $0.43 | $21,500.00 |
DisclosureSEC source: 0001209191-22-054744 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,244 F1 · shares: Open market acquisition. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 16:49 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-048523 · doc4.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-08-31 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of August 31, 2023, 2024 and 2025, respectively. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 16:49 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048523 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,244 F1 · shares: Represents restricted stock units ("RSUs") granted on August 31, 2022. One hundred percent (100%) of the total number of RSUs granted vest on the earlier of (i) June 22, 2023 or (ii) the date of the Company's 2023 Annual Meeting of Stockholders. Read SEC document |
| February 14, 2022 Filed Feb 14, 2022 16:27 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 10,000 | $0.68 | $6,849.00 |
DisclosureSEC source: 0001209191-22-009266 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,244 F1 · shares: Open market acquisition. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 18:03 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 67,804 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001209191-21-042495 · doc4.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,804 Underlying: Common Stock · 67,804 shares Expires 2031-06-17 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of June 17, 2022, 2023 and 2024, respectively. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 18:03 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 14,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042495 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,244 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 17, 2022 or (2) the date of the company's 2022 Annual Meeting of Stockholders. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 14:26 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 20,000 | $3.15 | $63,000.00 |
DisclosureSEC source: 0001209191-21-026029 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,967 F1 · shares: Open market acquisition. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 16:47 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 10,000 | $3.61 | $36,100.00 |
DisclosureSEC source: 0001209191-21-011890 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,967 F1 · shares: Open market acquisition. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 17:15 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 10,000 | $3.79 | $37,900.00 |
DisclosureSEC source: 0001209191-20-065221 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,967 F1 · shares: Open market acquisition. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 18:05 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 10,000 | $3.78 | $37,800.00 |
DisclosureSEC source: 0001209191-20-058104 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,967 F1 · shares: Open market acquisition. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 09:57 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 1,000 | $4.24 | $4,238.10 |
DisclosureSEC source: 0001209191-20-050793 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,967 F1 · shares: Open market acquisition. Read SEC document |
| August 28, 2020 Filed Sep 1, 2020 15:49 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 20,000 | $4.08 | $81,600.00 |
DisclosureSEC source: 0001209191-20-048887 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,967 F1 · shares: Open market acquisition. Read SEC document |
| June 30, 2020 Filed Jun 30, 2020 16:10 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 8,000 | $3.21 | $25,680.00 |
DisclosureSEC source: 0001209191-20-039442 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,967 F1 · shares: Open market acquisition. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 17:22 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-20-037997 · doc4.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-06-18 F2 · derivative.exercise_date: One third of the aggregate amount of option shares shall vest on each of June 18, 2021, 2022 and 2023, respectively. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 17:22 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037997 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,967 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 18, 2021 or (2) the date of the company's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 15, 2020 Filed May 15, 2020 18:48 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 5,000 | $3.11 | $15,550.00 |
DisclosureSEC source: 0001209191-20-029852 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,967 Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:03 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 19,231 | $26.00 | $500,006.00 |
DisclosureSEC source: 0001209191-19-039462 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,231 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:19 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.44 | $0.00 |
DisclosureSEC source: 0001209191-19-038668 · doc4.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-20 F2 · derivative.exercise_date: 25% of the option shares vested on June 20, 2019. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:19 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038668 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,967 F1 · shares: 100% of the restricted shares shall vest on the earlier of (1) June 20, 2020 or (2) the date of the company's 2020 Annual Meeting of Stockholders. Read SEC document |
| May 13, 2019 Filed May 14, 2019 15:38 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 1,000 | $8.93 | $8,930.00 |
DisclosureSEC source: 0001209191-19-029584 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,967 Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 13:41 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 2,000 | $10.47 | $20,940.00 |
DisclosureSEC source: 0001209191-19-020228 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,967 Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 11:47 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 2,000 | $9.62 | $19,240.00 |
DisclosureSEC source: 0001209191-19-019902 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,967 Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 21:57 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 1,000 | $17.00 | $17,000.00 |
DisclosureSEC source: 0001209191-19-017812 · doc4.xml · nonDerivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| March 04, 2019 Filed Mar 7, 2019 21:57 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 2,000 | $17.00 | $33,999.80 |
DisclosureSEC source: 0001209191-19-017812 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001209191-19-001518 · doc4.xml · derivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-12-31 F1 · derivative.exercise_date: The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 20:20 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantStock Option (Right to Buy) · Derivative | 14,507 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-18-060701 · doc4.xml · derivative · entry 2 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,507 Underlying: Common Stock · 14,507 shares Expires 2028-11-30 F2 · derivative.exercise_date: 25% of the option shares vested on November 30, 2018. The remaining option shares shall vest in 25% equal annual amounts on each anniversary date of the grant over three years. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 20:20 UTC | SPECTRUM PHARMACEUTICALS INC SPPI · Entity 111009 | GrantCommon Stock, $0.001 par value | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-060701 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,967 F1 · shares: 100% of the restricted shares shall vest on June 19, 2019. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:52 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $24.73 | $0.00 |
DisclosureSEC source: 0001209191-18-002269 · doc4.xml · derivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on January 2, 2019. Read SEC document |
| December 12, 2017 Filed Dec 15, 2017 01:01 UTC | Odonate Therapeutics, Inc. ODT · Entity 132524 | PurchaseCommon Stock | 1,000 | $23.30 | $23,300.00 |
DisclosureSEC source: 0001209191-17-065777 · doc4.xml · nonDerivative · entry 1 Vacirca Jeff L · CIK 0001724161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.